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Abstract
Blood coagulation is a series of biochemical reactions that take place to form
a blood clot. Abnormalities in coagulation, such as under-clotting or over-
clotting, can lead to significant blood loss, cardiac arrest, damage to vital
organs, or even death. Thus, understanding quantitatively how blood co-
agulation works is important in informing clinical decisions about treat-
ing deficiencies and disorders. Quantifying blood coagulation is possible
through mathematical modeling. This review presents different mathemat-
ical models that have been developed in the past 30 years to describe the
biochemistry, biophysics, and clinical applications of blood coagulation re-
search. This review includes the strengths and limitations of models, as
well as suggestions for future work.
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Chapter 1
Introduction
A person’s survival is dependent on various physiological systems func-
tioning properly, including the cardiovascular system. One of the subsys-
tems of the cardiovascular system is known as hemostasis, or the process
by which clots are formed when blood vessels are damaged. Hemosta-
sis prevents blood loss while maintaining blood in a fluid state within the
vascular system (Barrett et al., 2010). Using complex, interrelated mecha-
nisms in the bloodstream, our bodies keep a balance between coagulation
and anticoagulation. If an imbalance occurs within this system, such as a
deficiency of certain proteins, our blood may not clot enough, resulting in
severe bleeding episodes. Conversely, our blood may clot too much, result-
ing in severe thrombotic (clotting) events. Some of the problems that may
arise from abnormal clotting include significant blood loss, pulmonary em-
bolism, deep vein thrombosis, stroke, cardiac arrest, or even death (Catta-
neo et al., 1998; Tanaka et al., 2009). Therefore, blood coagulation research
is important because it helps find and test treatments for many clotting ab-
normalities (Tanaka et al., 2009).
Blood coagulation is a complex process. Some areas of interest include
coagulation kinetics, the spatial organization of blood coagulation, the ef-
fects of blood flow on clotting, and the effects of drugs on the coagulation
system. However, studying these aspects of coagulation using only exper-
iments can be difficult because many of the nuances of blood coagulation
are difficult to recreate, observe and measure. Outside of research labs, it
is difficult to predict thrombotic events (like deep vein thrombosis or pul-
monary embolism) and it is challenging to determine how to treat these
disorders with current medications, particularly because so many genetic,
environmental, and dietary factors come into play (Oakley and Larjava,
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2012). As a result, various mathematical and computational models have
been developed in the past couple of decades to address some of these
areas. Mathematical models can provide details about blood coagulation
that may otherwise be unfeasible to attain with experiments. Despite the
insight these models can provide, there are also many simplifying assump-
tions that limit the models. In this chapter, we present a brief summary of
the biology and chemistry of blood coagulation, some of the complications
that arise in current clinical practices and therapies, and the uses of current
mathematical models.
In Chapter 2, we discuss mathematical models of the chemical kinet-
ics of coagulation. In particular, we will explore cascade-based and cell-
based models of coagulation, and the different mathematical approaches
taken in these models. Chapter 3 presents models of clot formation that in-
corporate the physiological, biochemical, and physical dynamics of blood
flow. In Chapter 4, we describe the clinical and pharmaceutical applica-
tions of blood coagulation models including the complexity of modeling
pharmacokinetic-pharmacodynamic (PK-PD) data and clotting abnormali-
ties, the role of models in drug development, and the potential use of math-
ematical models for individualistic medicine (i.e., developing individual
profiles of disease risk). We present some concluding remarks in Chapter 5.
1.1 What is blood coagulation?
Blood is a vital part of the human body that functions to transport nutrients
and oxygen throughout our system and eliminate waste via blood vessels.
Blood has two main components: cells and plasma. Blood cells include
red blood cells, whites blood cells, and cell fragments known as platelets
(Barrett et al., 2010). Platelets are important in coagulation because they
aggregate at the site of injury of the blood vessel (Barrett et al., 2010; Furie
and Furie, 2008). Plasma is the liquid part of blood. It is composed of
proteins, clotting factors, gases, and other small particles (Figure 1.1).
However, damage to blood vessels occurs frequently. When this hap-
pens, the body has a system in place, known as hemostasis, to stop bleed-
ing. The first part of hemostasis involves vascoconstriction, or the con-
striction of the vessel wall, to reduce the blood flow to the injury site and
decrease blood loss (Barrett et al., 2010). Platelets then start to stick to the
injured blood vessel to form a soft plug. Platelets also activate the last step
of hemostasis, blood coagulation, which changes blood from a liquid to a
gel and ultimately forms a blood clot.
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Figure 1.1 Blood is composed of various substances including red blood
cells, white blood cells, platelets, and plasma. Image taken from Under-
standing Blood and Blood Components. Fairview Health Services, n.d. Web.
<https://www.fairview.org/HealthLibrary/Article/40309>.
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1.1.1 Biological Models of Coagulation
In order to solidify the initial clot that is formed in the first part of hemosta-
sis, there are substances known as clotting factors that biochemically inter-
act with one another. These interactions result in the formation of fibrin,
which is initially a loose mesh of strands that interlace with platelets to
form a clot, as seen in Figure 1.2 (Barrett et al., 2010).
One important thing to note is that there are two different biological
models that are used to describe hemostasis: the coagulation cascade and
a cell-centric model. Developed in the mid-1960s, the coagulation cascade
model was the first widely accepted model of coagulation (Oakley and Lar-
java, 2012). The cell-centric model was developed in the early 2000s (Oak-
ley and Larjava, 2012). Today, it is important to understand these biological
models because they are both being used to develop mathematical models,
diagnostics and therapies. In particular, several of the diagnostic tests used
to evaluate an individual’s ability to clot are based on the coagulation cas-
cade (Oakley and Larjava, 2012). The cell-centric model of hemostasis is
important because researchers are starting to incorporate the cellular con-
straints from the model into their work (Butenas et al., 2009; Riddel et al.,
2007). We will discuss what the differences between these two models are
and what their roles are in this area of study.
Notation
The notation used to name clotting factors are Roman numerals, with an
"a" following the Roman numeral if the clotting factor is activated (Barrett
et al., 2010). They can abbreviated by placing an "f" before the Roman nu-
meral (e.g., factor IIa→ fIIa, factor V→ fV).
Extrinsic and Intrinsic Pathways
Most of the reactions that take place during coagulation occur via two dif-
ferent pathways: the extrinsic pathway and the intrinsic pathway. The ex-
trinsic pathway is the faster of the two pathways and is initiated by a pro-
tein known as tissue factor (TF). TF is one of the proteins that is released
by damaged blood vessels to initiate coagulation (Butenas and Mann, 2002;
Jesty and Beltrami, 2005; Jones and Mann, 1994; Mann et al., 2003; Tanaka
et al., 2009). Note that TF is also found on the surfaces of other blood cells,
which can also initiate blood coagulation in vivo. In the extrinsic pathway,
thrombin is generated by the interactions of fVII (See Figure 1.2). In con-
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trast, the intrinsic pathway is much slower than the extrinsic pathway and
is activated by a number of factors including: platelets, the small amount
of thrombin produced by the extrinsic pathway, exposed subendothelium,
or damage to the inside of the vascular system. In particular, the intrin-
sic pathway reactions involve fVIII, fIX, and fXI. These clotting factors and
their associated biochemical reactions are responsible for sustaining coag-
ulation once the cascade has started to generate thrombin (Butenas and
Mann, 2002; Jesty and Beltrami, 2005; Jones and Mann, 1994; Tanaka et al.,
2009).
Blood Coagulation Cascade
The coagulation cascade is governed by the concentration and reactions
of the clotting factors and proteins. This model of coagulation has three
principal components (See Figure 1.2).
1. Extrinsic Pathway. Coagulation can be initiated by the extrinsic path-
way, meaning the subendothelium is damaged and TF is released.
Eventually this results in the formation of fXa (Jesty and Beltrami,
2005; Jones and Mann, 1994; Mackman et al., 2007; Riddel et al., 2007).
2. Intrinsic Pathway. Coagulation can also be initiated through this
pathway, meaning that all the necessary components needed to clot
are found in the blood, without the need to expose other cells. This
pathway also results in the activation of fX to fXa (Jesty and Beltrami,
2005; Jones and Mann, 1994; Riddel et al., 2007).
3. Common Pathway. Regardless of how the cascade is initiated, the
complex known as prothrombinase (fXa:fVa) is formed. Both path-
ways eventually meet in the common pathway, where they finish
forming a clot. The common pathway involves fI, fII, fV, and fX. In
this pathway, the end result is the activation of fibrinogen (fI) to fibrin
(fIa), and the fibrin forms a polymer that helps stabilize the location of
the soft plug originally made in the first steps of hemostasis (Butenas
et al., 1997; Jesty and Beltrami, 2005; Jones and Mann, 1994; Tanaka
et al., 2009).
Even though coagulation can be initiated by either the intrinsic or extrinsic
pathway, in general, it is thought that the extrinsic pathway initiates coag-
ulation in tissue factor (TF) induced-coagulation. It is faster and forms a
temporary plug that is stabilized by the longer intrinsic pathway and the
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common pathway (Jesty and Beltrami, 2005; Jones and Mann, 1994; Oakley
and Larjava, 2012).
This model of coagulation is adequate enough to explain plasma-based
in vitro coagulation. As a result, many of the diagnostic tests that are used
to detect clotting abnormalities in patients are based on this model. Note
that in many of the models, the results are often presented by the amount
of thrombin produced over time. This is because the formation of thrombin
(fIIa) is the penultimate step in clotting and necessary for the activation of
fibrinogen to fibrin, which is catalyzed by thrombin (See Figure 1.2). This
makes thrombin an important species in the reaction, and thus an appro-
priate concentration to keep track of when evaluating coagulation.
Cell-Centric Model of Hemostasis
In contrast, the cell-centric model of hemostasis has four different phases,
listed below (Hoffman and Monroe-III, 2001; Oakley and Larjava, 2012).
1. Initiation Phase. Just as in the coagulation cascade, the clotting pro-
cess is initiated by TF from the subendothelial cells, and ultimately
results in the production of small concentrations of the following clot-
ting factors: fXa, fIXa, and thrombin.
2. Amplification Phase. If there are enough procoagulant substances
generated, then the amplification phase is activated (Oakley and Lar-
java, 2012). In the amplification phase, the coagulation moves from
the tissue factor (TF) bearing cells to platelets. The thrombin that
is generated in the initiation phase activates the platelets and the
platelets begin to stick together and form a clot (Oakley and Larjava,
2012).
3. Propagation Phase. Once the platelets are activated, the other clot-
ting factors necessary to form fibrin bind to the platelet and react,
resulting in even more thrombin production (Oakley and Larjava,
2012).
4. Termination Phase. Lastly, the termination phase ends with the for-
mation of the stable clot (Oakley and Larjava, 2012).
An overview of this model can be seen in Figure 1.3.
Unlike in the coagulation cascade, in the cell-centric model the extrin-
sic and intrinsic pathways do not operate separately to initiate coagulation.
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Figure 1.2 (a) An overview of hemostasis. (b) The coagulation cascade
model. The extrinsic and intrinsic pathways work separately and eventually
meet in the final common pathway. In the common pathway, thrombin and fib-
rin are generated, leading to the formation of a fibrin clot. Image taken from
Hemostasis. Candela Open Courses: Anatomy and Physiology II, n.d. Web.
<https://courses.candelalearning.com/ap2x2master/chapter/hemostasis/>.
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Rather, both pathways work together to form a clot but the pathways func-
tion on different blood vessel surfaces (Oakley and Larjava, 2012). The ex-
trinsic pathway operates on the TF-bearing cell that initiates and amplifies
coagulation (Oakley and Larjava, 2012). The intrinsic pathway works on
platelet surfaces to generate the large concentrations of thrombin and other
substances needed to form a fibrin clot (Oakley and Larjava, 2012).
Spatial Organization of Blood Coagulation
Platelets play an important role in blood coagulation because they stick to-
gether at the site of injury on a blood vessel (Barrett et al., 2010). Also, sev-
eral of the reactions that take place in blood coagulation are only possible
in the presence of platelets. This is because many of the proteins in blood
need to be bound to platelets on binding sites for reactions with other pro-
teins to take place (See Figure 1.4).
Because of the finite number of binding sites available on platelets,
platelets also regulate blood coagulation. In addition, platelet binding sites
come in two states: an activated and inactivated state. When platelets are
activated, they begin to bind to the subendothelium at the injury site and
to each other (Oakley and Larjava, 2012).
Another component of blood clotting that contributes to the spatial or-
ganization of coagulation is blood flow. Blood flow not only transports dif-
ferent clotting factors throughout the blood vessel, but also affects the rate
at which a clot is formed (Figure 1.5) (Tanaka et al., 2009). Because blood
flow diffuses clotting factors throughout the body, blood flow adds more
complexity to the understanding of blood coagulation. Blood flow creates
a spatial heterogeneity in clotting, meaning that where reactions take place
matters (Oakley and Larjava, 2012). For instance, different types of blood
vessels (i.e., arteries and veins) have different physiological characteristics
that affect how a clot is formed (see Chapter 3).
1.2 Clinical Importance of Blood Coagulation
Research in blood coagulation is motivated by the clinical importance of
understanding abnormalities in clotting. Two ways that research in blood
coagulation is applied to medicine includes diagnostics and pharmacology.
Current understanding of blood coagulation directly influences the types
of screening tests that are used to detect and diagnose clotting abnormali-
ties in individuals. Similarly, this knowledge is applied to the development
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Figure 1.3 The cell-centric model of hemostasis has four principle phases: (A)
the initiation phase, (B) the amplification phase, (C) the propagation phase, and
(D) the termination phase. In this model, the extrinsic and intrinsic pathways
work in parallel but on different surfaces. The extrinsic pathway operates on the
initiation and amplification phases on the TF-bearing cells that initiate coagula-
tion. The intrinsic pathway works in the propagation and termination phase on
platelet surfaces to generate the thrombin burst needed to form a clot. Image
taken from Oakley and Larjava (2012).
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Figure 1.4 Platelets have a finite number of binding sites on their surface that
are available for proteins and clotting factors to adhere to. These binding sites
are designed so that only specific clotting factors can bind to these sites, making
platelets another mechanism of regulation in coagulation. Many of the reactions
that take place in blood coagulation can only take place if they are bound to the
surface of activated platelets.
Figure 1.5 Blood coagulation takes place in spatially heterogeneous environ-
ment, meaning that different reactions occur at different locations. Blood flow
is essential in regulating blood coagulation because it diffuses active factors
throughout the system. Image taken from Shibeko and Panteleev (2015).
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of drug treatments for individuals with clotting abnormalities. Ultimately,
researchers would like to develop individual profiles of disease risk, but
there are several external factors (i.e., preexisting health conditions, envi-
ronmental factors) that complicate this endeavor (Brummel-Ziedins et al.,
2014).
1.2.1 Clotting Abnormalities
When an individual has clotting abnormalities, it can result in over-clotting
or under-clotting. An example of a hereditary clotting disorder is hemophilia.
There are two types of hemophilia: hemophilia A (fVIII deficiency) and
hemophilia B (fIX deficiency) (Bjorkman and Berntorp, 2001; Tanaka et al.,
2009). Both of these deficiencies slow down clotting times, which leads
to under-clotting. The severity of the under-clotting can vary greatly such
that injuries to some individuals may not pose a great risk but for those
with more extreme deficiencies, a small injury could lead to over-bleeding,
or even death (Tanaka et al., 2009). Similarly, over-clotting can lead to dan-
gerous conditions like coronary thrombosis or deep vein thrombosis. These
can lead to strokes, cardiac arrest, or death (Oakley and Larjava, 2012). As
in hemophilia, the symptoms and severity of thrombosis can vary from in-
dividual to individual.
However, other diseases and health conditions can also lead to acquired
bleeding disorders. For instance, liver diseases affect the production of clot-
ting factors (Oakley and Larjava, 2012). Regular use of medications taken
to manage chronic pain or heart conditions also affects platelet functions or
clotting factor expression (Oakley and Larjava, 2012).
Because of the great risk that clotting abnormalities pose for individu-
als, several prophylactic and therapeutic treatments have been developed.
One of the major goals of anticoagulant treatments is to reduce the risk
of over-bleeding without increasing the risk of other thrombotic events
(Bjorkman and Berntorp, 2001; Tanaka et al., 2009). As a result, it is increas-
ingly important to understand the pharmacokinetic-pharmacodynamic pro-
files of the new drugs and the residual effects of other treatments on blood
coagulation. Some of the more common medications prescribed for throm-
bosis include heparin, warfarin, coumadin and rivaroxaban (Bjorkman and
Berntorp, 2001; Oakley and Larjava, 2012). These anticoagulants each tar-
get different parts of the coagulation system. While understanding these
drugs is challenging because coagulation is a complex system, external fac-
tors can further complicate studying drug therapies. For example, many
foods, medications, medicinal herbs, supplements and drugs can interact to
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affect the pharmaceutical effects of prescribed therapies (Brummel-Ziedins
et al., 2014; Oakley and Larjava, 2012).
1.2.2 Diagnostic Tests
Currently, two of the most common screening tests for coagulation abnor-
malities are the prothrombin time test (PT) and the activated partial throm-
boplastin time test (aPTT) (Dudek et al., 2011a; Lancé, 2015; Tanaka et al.,
2009). The PT test evaluates the extrinsic pathway of the coagulation cas-
cade. In this test, a large amount of TF is added to a blood plasma sample.
This test uses significantly more TF than would be found in vivo, or in the
body. This leads to faster thrombin generation than is observed in the body
(Dudek et al., 2011a; Tanaka et al., 2009). In addition, these tests do not
accurately measure clotting abnormalities in patients because normal PT
levels are seen in patients with hemophilia (Tanaka et al., 2009). Thus, a PT
test alone is not enough to determine what type of deficiency a patient has
(Butenas and Mann, 2007).
To account for the inaccuracies presented in the PT test, the aPTT test
was developed. In this test, there are lower concentrations of TF which lim-
its the production of thrombin. As a result, more realistic thrombin levels
are observed in these tests. Hence, aPTT is used to evaluate the effects of
anticoagulants like heparin (Lancé, 2015; Tanaka et al., 2009). Just as the
PT test, this test evaluates clotting assuming that the coagulation cascade is
the correct biological model. The difference is that the aPTT looks at both
the intrinsic and extrinsic pathways, whereas the PT test only looks at the
extrinsic pathway (Lancé, 2015; Tanaka et al., 2009).
While these clot time tests provide useful insights into the blood coagu-
lation of an individual, they fail to account for other aspects of blood coag-
ulation. For example, both the PT and aPTT tests are stopped when fibrin is
first formed (Lancé, 2015; Oakley and Larjava, 2012). This means the tests
are not able to accurately determine the quality of the clot that is formed
because they do not allow enough time for the clot to stabilize. They also
do not describe the in vivo interaction of coagulation factors with platelets.
Additionally, the results of these tests under prolonged conditions is highly
dependent on the platelet count (Oakley and Larjava, 2012). The tests are
also based on the coagulation cascade model. This assumes that the extrin-
sic and intrinsic pathways work separately, as opposed to them working in
parallel and dependent on specific cellular surfaces, like in the cell-centric
model (Oakley and Larjava, 2012).
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1.3 Mathematical Modeling
Blood coagulation is a complex system. There exist different biological
models to describe the system. There are several clotting abnormalities
that can result in under-clotting and over-clotting. These abnormalities
can lead to severe health complications in individuals. The interactions
between different therapies that treat these abnormalities, along with other
medications, food, supplements, drugs can complicate the investigations
of these therapies. Even detecting the abnormalities in the first place can
prove to be difficult. With such complexity involved in all aspects of blood
coagulation, mathematical models become useful.
Mathematical modeling allows researchers to explore and quantitatively
describe some of the nuances in blood coagulation that may not be obvious
from experiments alone. They can provide a safe way to explore different
treatments before testing and administering them to patients (Mann et al.,
2006; Mann, 2012). Mathematical models can also provide a way to explore
different screening tests. But, in order to investigate different areas and an-
swer different questions, a variety of mathematical modeling approaches
have been taken. In the following chapters, these different modeling ap-
proaches are discussed. They are put into context by identifying the moti-
vations and significant results of key models.

Chapter 2
Modeling the Chemical
Kinetics of Coagulation
Researchers are interested in understanding the theoretical underpinnings
of blood coagulation but because coagulation is so complex modelers have
tended to focus on specific parts of the process. One of the major areas of
interest is the biochemistry of clotting. Many of these models only describe
the coagulation cascade and ignore the spatial and flow components of co-
agulation (e.g. Bungay et al., 2003; Brummel-Ziedins et al., 2012a, b; Guo
et al., 2006; Higgins et al., 1983; Hockin et al., 2002; Jones and Mann, 1994;
Khanin et al., 1998; Kogan et al., 2001; Luan et al., 2007; Xu et al., 2002, 2005).
These type of models primarily focus on describing the protein concentra-
tions over time by using a series of nonlinear, ordinary differential equa-
tions (ODEs). While these types of deterministic models are common, in an
effort to create more physiologically relevant models, there has been some
work done to implement a stochastic model of the coagulation cascade (Lo
et al., 2005). In this chapter, we will provide an overview of mathematical
models that have been developed to describe the coagulation cascade.
Mathematical models that are concerned with describing the biochem-
ical reactions of coagulation usually derive a system of ODEs or partial
differential equations (PDEs) based on the reactions. To derive these equa-
tions, they use the law mass action, Michaelis-Menton equations, or other
chemical considerations. The law of mass action and the Michaelis-Menten
equations allow for a system of equations to be directly derived from a
chemical reaction. This approach takes into account the different concen-
trations of proteins and the reaction rate constants of each reaction involved
in coagulation. The concentrations and rate constants used in these models
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are derived empirically and taken from literature.
2.1 Models of the Coagulation Cascade
Many of the mathematical models of the coagulation cascade have taken
a deterministic approach (e.g. Brummel-Ziedins et al., 2012a, b; Bungay
et al., 2003; da Cunha Orfao, 2007; Guo et al., 2006; Hockin et al., 2002;
Jones and Mann, 1994; Khanin et al., 1998; Kogan et al., 2001; Lee et al.,
2010; Luan et al., 2007, 2010; Makin, 2008; Mitrophanov and Reifman, 2011;
Mitrophanov et al., 2012, 2014; Sagar and Varner, 2015; Xu et al., 2002, 2005).
They use a system of equations that are solved numerically to track the con-
centration of proteins over time.
One of the most widely used models is presented by Hockin et al. (2002).
This model uses a system of 34 nonlinear ODEs with 42 rate constants to
describe the extrinsic blood coagulation system. It includes anticoagulants
tissue factor pathway inhibitor (TFPI) and antithrombin-III (TFPI and AT-
III), the vitamin K-dependent procoagulant complexes, and binding com-
petition between TF and factors fVII and fVIIa, which are critical compo-
nents of coagulation biochemistry (Butenas and Mann, 2002). This model
is of particular importance because it was validated by comparing numer-
ical simulations to empirical in vitro data (Figure 2.1). The model’s abil-
ity to capture most experimentally observed parameters and behavior for
both normal, enhanced, and deficient in vitro thrombin generation made it
widely accepted. Many more complex models are based on this relatively
simple model. However, this model fails to include the intrinsic pathway
and platelet dynamics. Inclusion of the intrinsic pathway is important be-
cause the intrinsic pathway ensures the blood clot is stabilized and will
remain in place to help the damaged vessel heal (Barrett et al., 2010). With-
out the intrinsic pathway, the temporary clot formed quickly in the extrin-
sic pathway could be dislodged. Platelets are also important to include in
the model because the finite number of binding sites available on platelets
is an added constraint on the amount of thrombin that can be produced
(Oakley and Larjava, 2012). In reality, the number of platelets that are ac-
tivated changes as coagulation takes place. However, Hockin et al. (2002)
assumes a maximally activated platelet at t = 0. Another pitfall of this
model is that it is able to accurately predict the initiation times of coagula-
tion at picomolar levels of TF, but it fails to do so at sub-picomolar levels.
There exist more complete models of the coagulation cascade. For ex-
ample, Bungay et al. (2003) includes a system of 73, nonlinear ODEs that
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Figure 2.1 These figures are the results from numerical and experimental work
that shows the active thrombin concentration as a function of time with varying
concentrations of prothrombin. The experimental conditions include 150% (filled
diamonds), 125% (filled triangles), 100% (filled squares), 75% (filled circles), and
50% (asterisk) of normal prothrombin concentrations. A: The numerical results
of Hockin et al. (2002) with the aforementioned conditions. B: Empirical data.
C: Numerical results of thrombin produced under the experimental conditions of
A and B with the presence of 1% fVa contamination in fV. Note that this con-
tamination was part of the experimental results. Image taken from Hockin et al.
(2002).
describes all of the extrinsic pathway, a significant portion of the intrin-
sic pathway, and the presence of lipids, up to the formation of thrombin. A
slightly more complete model is presented by Luan et al. (2007). This model
includes 92 nonlinear ODEs and is similar to the Bungay et al. (2003) model,
but includes the effects of platelets on overall thrombin production. Includ-
ing these aspects of blood coagulation can better help detect and determine
coagulation abnormalities.
2.1.1 Applications: Studying Coagulation Abnormalities
These simple models form the basis of other models that help researchers
find potential ways to improve the diagnosis of abnormal clotting. To
demonstrate, Brummel-Ziedins et al. (2012b) uses the Hockin et al. (2002)
model with some modifications to compare fXa formation with thrombin
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formation. Including this comparison is useful in modeling because the
biology of coagulation shows that when fXa activates prothrombin, throm-
bin is formed (See Chapter 1). Making sure that this behavior is captured
is essential in creating more accurate models. In the Brummel-Ziedins
et al. (2012b) study, numerical simulations are run by using a mathemat-
ical model along with empirical data collected from patients with normal
coagulation and deep vein thrombosis (DVT).
Understanding fXa generation has become increasingly important to
the development of anticoagulants. By targeting fXa, which is needed for
thrombin formation, clotting can be decreased (Brummel-Ziedins et al.,
2012b). Thus, a more accurate way of monitoring and evaluating the ef-
fectiveness of these treatments is needed. While Brummel-Ziedins et al.
(2012b) contributed to the current understanding of fXa and thrombin gen-
erations, the model did not include the protein C pathway, the effects of
platelets, or the intrinsic pathway.
In addition, a similar type of model was developed by the same group,
Brummel-Ziedins et al. (2012a). In this model, they add the protein C path-
way to the extrinsic pathway model. The protein C pathway is a pathway
that helps regulate anticoagulation in the system (Tanaka et al., 2009). Us-
ing this slightly different approach, the group is able to show that a large
protein C (PC) deficient family is not prone to thrombosis simply because
of this deficiency. In fact, regardless of an individual’s PC status there ap-
peared to be procoagulant tendency among family members. These pro-
coagulant tendencies were multicausal, and were further explained by in-
dividual plasma composition (Brummel-Ziedins et al., 2012a). Hence, this
model suggests that plasma-based composition models are useful in un-
derstanding coagulation tendencies in individuals, and may even provide
insight into other parts of the coagulation cascade that may be leading to
thrombotic events.
These models are also used to study the dynamics of the clotting ab-
normalities. For instance, (Shavlyugin et al., 2014) uses a modified version
of the in vitro intrinsic pathway model presented by Khanin et al. (1998) to
study pathologic clot formation (clots that cause, or are formed by, disease).
Their work modeled the intrinsic pathway system, including platelets and
their activation. In Shavlyugin et al. (2014), the authors made the assump-
tion that rate of pathologic clot formation is much lower than the rate of
formation of a normal clot. This allowed them to simplify their model
and ultimately estimate the kinetic rate constants that initiate pathologic
clot formation. Based off of their model, the authors were able to deter-
mine which factors may inhibit pathologic clot formation, which could ul-
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timately inform the decisions of researchers and physicians.
Note that these models can also be used to study the effectiveness of
treatments of clotting abnormalities. This is further discussed in Chapter 4.
2.1.2 Sensitivity Analysis
The deterministic models of blood coagulation are solved as if the empiri-
cally derived parameters, such as rate constants, are known with certainty.
However, there is a certain amount of uncertainty associated with each of
the parameters in these models. As such, sensitivity analysis has been per-
formed on some of these models. This allows researchers to know where
measurement accuracy should be improved and where a model’s ability to
predict coagulation behavior fails. Despite this being an area that should be
studied, as of writing, there are only very few papers that perform a sen-
sitivity analysis of mechanistic models (Danforth et al., 2009, 2012; Luan
et al., 2007).
The Danforth et al. (2009) paper directly addresses the uncertainty in
parameters. This is important because many of the rate constants are mea-
sured from experiments, and others are derived indirectly from other mea-
sured quantities (Danforth et al., 2009). This means that there is uncertainty
associated with the parameters used in the model. In this work, the authors
perform a sensitivity analysis of the widely used Hockin et al. (2002) model
and the values used for the rate constants. The values of 44 rate constants
are varied an order of magnitude above and below the used values. The
variation of the concentrations are quantified using a normalized standard
deviation. This study concludes that the model is most sensitive to un-
certainty in five rate constants that are involved in regulation of fVII-TF
complex, accounting for 50% of the aggregate variation. This suggests that
the regulation of fVII-TF complex is a mechanism where more care should
be taken when measuring the rate constants of the reactions.
Another paper by Luan et al. (2007) used sensitivity analysis of the
coagulation cascade to determine the fragility of specific sites in the cas-
cade. They developed a deterministic model that included all of the extrin-
sic pathway, most of the intrinsic pathway, and the effects of platelets on
thrombin generation. The authors used a Monte Carlo strategy in which
the best-guess parameter values were used to generate a random param-
eter set. Ultimately, they found that fX/fXa and prothrombin/thrombin
(fII/fIIa) were the most sensitive parameters, which is consistent with throm-
bosis therapies that target fX and thrombin. This suggests that sensitivity
analysis can be used to determine potential targets in coagulation therapies,
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despite the uncertainties in the model parameters.
However, the uncertainties in the parameters still pose problems. In
such cases, sensitivity analysis can help reveal problems with a model. For
instance, a more recent study performed by Danforth et al. (2012) used
a model similar to that used in the work of Luan et al. (2007) (based on
Hockin et al. (2002)) to investigate how normal range variation of differ-
ent initial concentrations of clotting factors normally found in plasma of
in vitro experiments affects total thrombin output. Numerical simulations
were run to create thrombin profiles of both healthy individuals and those
with deficiencies. These results were compared to empirical data taken di-
rectly from patients. The results of this study found that the normal range
of variation for healthy individuals was not significantly different from the
profiles of individuals with clotting abnormalities, suggesting that more
work should be done to address the uncertainty that exists in these mod-
els. While more extreme cases were distinguishable from normal variation,
less extreme cases of clotting abnormalities were not distinguishable. In
particular, this work is interesting because it seems to be in opposition to
the work done by Luan et al. (2007), which states that despite the model’s
uncertainty it accurately describes what is seen in therapies. The work
done by Danforth et al. (2012) shows that the normal variations observed
in plasma content is not accurately described by the models. Thus, it seems
that more work is necessary to confirm whether the uncertainties seen in
the deterministic models are negligible because just looking at one part of
the uncertainty yields different results. One possible study that could be
done would be to do a sensitivity analysis that takes into account the rate
constants (Danforth et al., 2009), the interactions of the different clotting
factors (Luan et al., 2007) and the initial concentrations of clotting factors
in plasma (Danforth et al., 2012).
2.2 Cell Based Models of Coagulation
One of the major milestones in blood coagulation modeling is the develop-
ment of cell based models (Brummel-Ziedins, 2014; Chatterjee, 2011; Chat-
terjee et al., 2010; Diamond, 2013; Makin, 2008; Nielsen, 2008; Nielsen et al.,
2009). Cell based models are important because they allow for more spe-
cific modeling of the chemical kinetics of coagulation. For instance, they
more accurately capture the platelet dynamics by describing the activa-
tion process of platelets and the finite number of binding sites on a platelet
(Hemker et al., 2012; Smith, 2009). Ultimately, these models allow for more
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individualistic plasma profiles to be represented, leading to better diagnos-
tics and research results (Brummel-Ziedins, 2014).
All of the models that have been discussed make the assumption that
coagulation is TF-initiated. However, there exist other proteins that can
trigger clot formation. For instance, Chatterjee et al. (2010) uses experi-
ments to show that even when inhibitors, like corn trypsin inhibitor (CTI),
are used to block specific factors (CTI blocks FXIIa), CTI can build up enough
to initiate coagulation without TF being added to a blood sample. Us-
ing their experimental results, Chatterjee et al. (2010) developed an ODE-
based platelet plasma model based on the work of Hockin et al. (2002). This
model is important because it was the first model with the ability to predict
the observed behavior of CTI treatments in blood that contains activated
and inactivated platelets. This model takes a systems biology approach that
focuses on accounting for the autocatalytic feedback loops, and the non-
linearity of reaction rates (Diamond, 2009; Shahzad and Loor, 2012), and
the sensitivity of the model to initial conditions. Note that autocatalytic
feedback loops occur when the product of a reaction is itself the catalyst
for that same reaction. Overall, the Chatterjee et al. (2010) platelet plasma
model agreed more with experimental data (taken from literature) than the
Hockin et al. (2002) model (Figure 2.2).
The Chatterjee et al. (2010) model is well-suited for modeling in vitro
blood coagulation. The main assumption made in the model is that the
system is a well-mixed static system. While it does account for some of
the platelet dynamics of coagulation, it does not take flow and spatiotem-
poral dynamics present in in vivo systems into consideration. Despite its
inability to model in vivo coagulation, the platelet plasma model is a sig-
nificant contribution to the field because it suggests that individual blood
profiles can be taken into account in in vitro tests currently used in diag-
nostics and treatments (Flamm et al., 2012; Nielsen et al., 2009; Wang and
King, 2012). This insight also helped inform other types of models that take
into account flow dynamics (Bellini et al., 2014; Brummel-Ziedins, 2014;
Brummel-Ziedins et al., 2012b; Colace et al., 2012; Diamond, 2013; Fogel-
son et al., 2012; Lee et al., 2012; Leiderman and Fogelson, 2014). The use
of cell based models in more complex models, like those describing flow,
spatiotemporal phenomena, or treatments, will be discussed in detail in
Chapter 3.
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Figure 2.2 Simulations using the Chatterjee et al. (2010) (platelet plasma
model) and Hockin et al. (2002) models computed clotting times with additions
of TF, thrombin, fIXa, fXa, or combinations of the three clotting factors at low and
high doses. Results were compared to experimental data (labeled as Butenas et
al. in the figure). Note: the platelet plasma model more closely matched exper-
imental results than the Hockin et al. (2002) model, which only predicted finite
clotting times under high doses of TF or fXa. Image taken from Chatterjee et al.
(2010).
2.3 Stochastic Model
A different approach that has been taken to these deterministic models is
the development of stochastic models (Castaldi et al., 2013; Lo et al., 2005;
Makin and Narayanan, 2008). This is important because a stochastic model
can capture more of the variation associated with blood coagulation. One
such stochastic model of the coagulation network is presented by Lo et al.
(2005). Here, the authors aim to understand the dynamics of a system
with small numbers of TF molecules in a small local volume of blood. In
this model, Monte Carlo simulations are used along with the deterministic
model from Hockin et al. (2002) to capture the variability seen in low con-
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Figure 2.3 The total thrombin concentration for varying TF concentrations for
two different models is presented here. a: Hockin et al. (2002), a deterministic
model, results in the following numerical solutions of thrombin production over
time. b: Lo et al. (2005), a stochastic Monte Carlo model, yields the following
numerical solutions of thrombin production over time. Image taken from Lo et al.
(2005).
centration experiments. These simulations are governed by two questions:
(1) What time does the next reaction occur? (2) What kind of reaction will
it be? Each species involved in the reactions has a specific probability of
reacting with other species. The results from this model are comparable
with the results from Hockin et al. (2002) (Figure 2.3). However, while this
is a stochastic model that attempts to creates a more realistic description of
when reactions occur, it was unable to model clotting times in low concen-
trations of TF, and still ignores the uncertainty that exists in the parameters
that are used in the model.
In contrast, Castaldi et al. (2013) uses Petri nets to model the biochemi-
cal pathways of coagulation. A Petri net is defined as a weighted, directed
bipartite graph that can be used to study complex models (Castaldi et al.,
2013). This study is governed by the same questions as the work of Lo et al.
(2005), but Castaldi et al. (2013) uses a tau-leaping method to determine
when a reaction occurs. In this method, a small value τ is chosen such that
in the simulation there is a leap along the time axis in steps of length τ. At
each of these events, many single reactions can take place. Unlike Lo et al.
(2005), this model is able to work accurately under low concentrations of
TF.
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2.4 Conclusions
Modeling the biochemistry of blood coagulation is complex, and one must
choose the appropriate approach to answer the question at hand. Thus,
several mathematical approaches have been taken, including ODE-based
models, Monte Carlo simulations, and Petri net models. Modelers have
come from several disciplines, such as mathematics, systems biology, and
engineering. This suggests that modeling the chemical kinetics of coagula-
tion is of great interest.
The current models that describe in vitro blood coagulation are useful
in predicting coagulation behavior in experimental and non-vascular envi-
ronments. Because of this assumption, they are unable to accurately rep-
resent the coagulation that characterizes in vivo environments, given that
these models fail to account for flow and the spatial heterogeneity that ex-
ists in in vivo coagulation (Mann et al., 2009). Despite this, these models are
able to provide valuable insight into the biochemistry of clotting and some
of the diagnostic tests that are employed to evaluate an individual’s ability
to form a clot.
It seems that one of the major steps needed is to perform more analysis
on the uncertainty of parameters in current models (Hopkins and Leipold,
1996; Tyurin and Khanin, 2005). There are some studies that have per-
formed a sensitivity analysis and statistical analysis on these types of deter-
ministic models. However, there has not been much work done to address
the uncertainty in parameters in stochastic models. The stochastic models
are more accurate because they account for the variation that takes place
when reactions occur but they assume that the governing parameters of
their model are known. More should be done to explore the uncertainty
in parameters of these models, especially if these models are to be used
to help make predictions for diagnostic and therapeutic procedures. Sim-
ilarly, more work should be done to evaluate how the uncertainties from
various sources (rate constants, individual plasma-content variation, and
variation in clotting factor interactions) affects the overall thrombin pro-
duction represented by a model.
Chapter 3
Mathematical Models of Clot
Formation Under Flow
Physiologically, blood coagulation takes place in a dynamic fluid environ-
ment. Theoretical and experimental efforts have been made to understand
the physical processes that specifically affect clot formation. Among these
physical processes are flow-mediated transport and platelet deposition (Shibeko
et al., 2009). However, one of the challenges facing modelers in this area is
the lack of understanding of how the dynamics of blood flow affects clot
formation (Leiderman and Fogelson, 2014; Shibeko et al., 2009). It is also
still unclear how new insights into the effects of physical processes in coag-
ulation may alter the current view of clot formation, which has been solely
based on biochemical research (see Chapter 1). Because of the complex-
ity and lack of thorough understanding of flow and thrombus formation,
pharmaceutical companies and physicians do not use flow-based models
to make diagnostic predictions or test drugs on patients (Shibeko and Pan-
teleev, 2015).
In this chapter we will explore the different mathematical and compu-
tational models that have been developed to describe thrombus formation
under flow. Some of the models have taken a biophysical-approach, fo-
cusing on how shear-thinning fluids, the rheology of blood and different
types of flow (e.g., laminar, convective) affect thrombus growth (e.g. Ap-
piah, 2013; Ataullakhanov and Panteleev, 2005b; Basmadjian et al., 1997;
Beltrami and Jesty, 2001; Bodnár and Sequeira, 2008; Buravtsev et al., 2010;
Capek, 2011; Jarm et al., 2007; Jordan, 2010; LaCroix, 2012; Lobanov and
Starozhilova, 2005; Luan, 2009; Makin and Narayanan, 2008; Pavlova et al.,
2015; Quarteroni, 2006; Robertson et al., 2008; Runyon et al., 2008; Sequeira
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and Bodnar, 2014; Sequeira and Janela, 2007; Sequeira et al., 2011; Storti
et al., 2014; van de Vosse, 2003; Weller, 2010; Xu et al., 2008, 2009, 2012).
We will also discuss models that address both the dynamics of flow and
the spatial organization of blood in blood vessels, including both the veins
and arteries (Alenitsyn et al., 2010; Anor et al., 2010; Appiah et al., 2011;
Fasano et al., 2013; Fragomeni et al., 2008; Xu et al., 2010). Noting the
difference of whether veins or arteries are being modeled and simulated
is important because of the differences in blood pressure associated with
each. Arteries are high-pressure vessels, meaning that flow is generally
faster in these vessels (Ku, 1997). In contrast, veins are low-pressure ves-
sels and have slower blood flow (Ku, 1997). We will also focus on models
that study platelet-mediated thrombosis and the spatial constraints asso-
ciated with this (Alenitsyn et al., 2010; Anand et al., 2003, 2005; Buravtsev
et al., 2010; Filipovic et al., 2008; Flamm et al., 2012; Fogelson et al., 2012; Fo-
gelson and Tania, 2005; Jarm et al., 2007; Jordan, 2010; Kuharsky and Fogel-
son, 2001; Leiderman and Fogelson, 2011; Lobanov and Starozhilova, 2005;
Luan, 2009; Panteleev et al., 2006; Pavlova et al., 2015; Robertson et al., 2008;
Sequeira et al., 2011; Storti et al., 2014; van de Vosse, 2003; Weller, 2010; Xu
et al., 2008, 2009, 2012; Zarnitsina et al., 1996).
3.1 Dynamics of Blood Flow
Many groups have focused on developing mathematical models of the ef-
fects of flow on clot formation. Taking into account the biophysical im-
plications of physiological blood flow is a complicated endeavor, particu-
larly because of the dynamic environment in which blood coagulation takes
place. Physiological blood coagulation takes place under blood flow and
is spatially nonuniform (Ataullakhanov and Panteleev, 2005a; Formaggia
et al., 2009). Much of the emphasis of the models has been placed on shear-
thinning fluid models, the rheology of blood, and how different types of
flow (e.g., laminar or convective) affect thrombus growth (Pompano et al.,
2008). Many of these models are concerned with modeling the heterogene-
ity observed in blood flow. As a result, most of the models use sophisti-
cated multiscale PDE approaches to integrate coagulation kinetics, platelet
deposition, and flow (Flamm, 2011; Flamm et al., 2012; Fogelson and Guy,
2008; Fogelson and Tania, 2005; Formaggia et al., 2009; Jarm et al., 2007; Jor-
dan, 2010; Kim, 2002; Kim et al., 2013; Leiderman and Fogelson, 2011; Luan,
2009; Makin and Narayanan, 2008; Papadopoulos et al., 2014; Pavlova et al.,
2015; Quarteroni, 2006; Robertson et al., 2008; Sequeira et al., 2011; Sequeira
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and Janela, 2007; Sorensen et al., 1999; Storti et al., 2014; van de Vosse, 2003;
Weller, 2010; Xu et al., 2009, 2010, 2012; Zarnitsina et al., 1996). However,
Flamm (2011) uses lattice kinetic Monte Carlo simulations of platelet aggre-
gation and deposition to account for the stochastic tendencies of the flow-
driven particle motions of blood flow, and Mounts and Liebman (1997)
uses stochastic activity networks (SANs). There are also models that fo-
cus on primarily on the blood flow effects (Appiah, 2013; Basmadjian et al.,
1997; Beltrami and Jesty, 2001; Bessonov et al., 2016; Bodnár and Sequeira,
2008; Buravtsev et al., 2010; Capek, 2011; Formaggia et al., 2009; Jarm et al.,
2007; Jordan, 2010; Kim, 2002; Kim et al., 2013; Lobanov and Starozhilova,
2005; Luan, 2009; Makin and Narayanan, 2008; Panteleev et al., 2006; Pa-
padopoulos et al., 2014; Pavlova et al., 2015; Robertson et al., 2008; Sequeira
and Bodnar, 2014; Sequeira and Janela, 2007; Sequeira et al., 2011; Weller,
2010; Xu et al., 2009, 2012). There are also models that include coagulation
kinetics with simplified treatment of flow (de Pillis et al., 2015; Fogelson
and Guy, 2008; Fogelson et al., 2012; Fogelson and Tania, 2005; Kuharsky
and Fogelson, 2001; Wajima et al., 2009).
One of the aspects of blood flow that has been studied is blood rheology
(Sequeira and Janela, 2007; Sequeira et al., 2011; Storti et al., 2014; van de
Vosse, 2003). For example, Bodnár and Sequeira (2008) uses a generalized
Newtonian model with shear-thinning viscosity to describe blood flow. In
this particular model, a blood clot was treated as an area with 100 times
higher viscosity than that of regular blood. The area was determined by
tracking fibrin concentration values over the entire area of interest. This
way of modeling blood flow is practical because it uses simplified rheolog-
ical conditions to model thrombus formation at injured blood vessels.
One notes in Figure 3.1 that the concentration of fibrin on the blood
vessel wall after 60 s of clotting activity is increased primarily in the clot-
ting area. However, the blood flow advection causes some of the fibrin to
be spread downstream from the injured vessel site (Furie and Furie, 2008).
This ultimately changes the clot’s shape. While this is a reasonable result,
because of its simplicity in modeling blood coagulation as a single contin-
uum model, Bodnár and Sequeira (2008) neglects the different types of flow
that physiologically take place (Capek, 2011). Capek (2011) presents an ar-
gument against single continuum models. The author claims that single
continuum models do not capture the stacking, or adhesion, of red blood
cells (RBCs) on the inside of curved arteries. This is due to the lower val-
ues of wall shear rate that are present along these curves (Ku, 1997). Capek
(2011) proposes using mixture theory, which involves modeling different
aspects of whole blood using different fluid types. While other models have
28 Mathematical Models of Clot Formation Under Flow
Figure 3.1 Fibrin concentration on a blood vessel surface is affected by blood
flow after 60 s of clotting activity. Image taken from Bodnár and Sequeira (2008)
taken to using mixture theory, many continue to use the single continuum
model. These models focus on small, specific regions of the circulatory sys-
tem. More holistic models of both the arterial and venous system were not
developed until very recently. One of the main reasons is because mix-
ture theory presents challenges when trying to define boundary conditions
(Capek, 2011).
3.2 Formation of Clots
The formation of clots (or thrombi) is an exciting topic to study because
recently there has been more experimental work done toward understand-
ing the interaction between the biophysical and biochemical processes in-
volved in clot formation. In particular, experimental investigators have
been researching thrombus permeability and the structural heterogeneity
during clot formation under flow (Furie and Furie, 2008; Leiderman and
Fogelson, 2014). Some of the methods used in this kind of experimental
research include intravital microscopy, other experiments on animals and
in vitro flow chambers (Cazzaniga et al., 2014; Colace et al., 2012; Dahlback,
2000; Jarm et al., 2007; Leiderman and Fogelson, 2014; Torres et al., 2009).
These types of experiments have been critical in advancing the understand-
ing of clot formation because they allow the measurement and visualiza-
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tion of thrombin concentrations in vitro.
Based on the physical research done to date, mathematicians have been
able to develop more accurate models of thrombus formation. Some of the
models developed capture part or the full "lifespan" of a clot, which can be
described in three stages: initiation, formation, and dissolution (or lysis)
(Anand et al., 2003, 2005; Cito et al., 2013; Diamond, 1999; Flamm, 2011; Fo-
gelson and Guy, 2008; Fogelson et al., 2012; Fogelson and Tania, 2005; Furie
and Furie, 2008; Kim, 2002; Kim et al., 2013; Kuharsky and Fogelson, 2001;
LaCroix, 2012; Leiderman and Fogelson, 2011; Luan, 2009; Jarm et al., 2007;
Wang and King, 2012; Weller, 2010; Xu et al., 2008, 2009, 2011, 2012). One of
the key characteristics of these types of models is that they are multiscale
models. This means that they incorporate submodels of different aspects
of clot formation (e.g., biochemistry, flow dynamics, or platelet dynamics,
to name a few). In particular, they model the effects of flow, spatial het-
erogeneity of blood, platelet deposition, and coagulation kinetics. Some
models take a broader approach and model dermal wound repair, as op-
posed to focusing on the small-scale healing in blood vessels (Dallon et al.,
2000; Jorgensen and Sanders, 2015).
Models of Thrombus Formation and Lysis
One of the models of that captured the formation of clots is found in Anand
et al. (2005). In this model, blood is modeled as a shear-thinning viscoelas-
tic fluid that contains coagulation factors, however, the authors assume that
these coagulation factors do not affect the velocity of the blood flow. The
blood clot is modeled as a highly viscoelastic fluid where coagulation fac-
tors are also present. The flow dynamics are modeled as a single continuum
fluid with simplified treatment of the coagulation kinetics that uses only 25
reactants (Capek, 2011).
The results of the Anand et al. (2005) model are presented in Figure 3.2.
These results agree with physical intuition. One of the main findings of
this study is that the model predicts that shear stresses are significantly
higher in regions where there is a clot as opposed to regions with only
whole blood. However, some of the drawbacks are that it is based on the
coagulation cascade, and that it does not take account for the entire cascade.
Specifically, it does not include the intrinsic pathway; it only includes the
extrinsic pathway. The problem with using such a model today is that
it is generally accepted that cell-based models of coagulation are correct
(Fasano et al., 2013). It also oversimplifies the rheology of whole blood.
Since the work of Anand et al. (2005), more sophisticated models have
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Figure 3.2 The spatial evolution of fibrin concentration during the lifespan of
clot including the formation, growth and lysis in whole blood. Image taken from
Anand et al. (2005)
been developed. For example, the first spatial-temporal model of platelet
deposition and blood coagulation under flow was presented in Leiderman
and Fogelson (2011). In this model, Leiderman and Fogelson (2011) suc-
cessfully model platelet aggregation and blood coagulation under flow.
They include coagulation kinetics, platelet deposition, and the interactions
between blood flow and the growing mass.
One of the significant things about this work is that it models the throm-
bus as a porous substance, allowing for specific information to be drawn
out about how advective and diffusive transport affects the growth of the
clot at different stages and locations (Leiderman and Fogelson, 2011). For
instance, one of the results presented in the paper is of a time sequence
from 10 minutes of clotting activity (Figure 3.3). Note that platelets and
fluid-phase clotting chemicals are flowing downstream. All of the results
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Figure 3.3 Using a novel spatial-temporal model of thrombus formation under
flow, Leiderman and Fogelson (2011) generated a time sequence of thrombus
growth at 50, 100, 150, . . . , 600 s (from left to right, top to bottom). The initial
tissue factor (TF) density was 15 fmol cm−1, with a shear rate of 1500 s−1.
The arrows represent the fluid velocity, which have uniform scaling. The bound
platelet concentrations range from 0 (dark blue) to Pmax (dark red). Image taken
from Leiderman and Fogelson (2011)
used in this paper are modeled assuming that the channel height is 60µm
and length 240µm. The injury that initiates the clotting is located at the
midpoint of the bottom wall, with a length of 90µm. Leiderman and Fo-
gelson (2011) found that after 50 s there is little effect to the flow despite
the platelets partially covering the injury. As the thrombus grows, how-
ever, the flow is perturbed. In particular, we note in Figure 3.3 that there is
spatial heterogeneity in the thrombus (indicated by the colors) and that the
flow is increased where the vessel width decreases and the flow decreases
when the vessel widens again.
The Leiderman and Fogelson (2011) model was the first comprehen-
sive continuum blood clotting model that incorporated multiple aspects of
blood coagulation. The model takes into account the porosity of the throm-
bus. The thrombus’s resistance to flow is incorporated by adding a bound
activated-platelet-dependent term to the Naiver-Stokes momentum equa-
tion. However, one of the caveats is that two of the biochemical parameters
used in the model were not taken from experimental literature. Despite
the uncertainty associated with these types of parameters, the study con-
firmed the model’s results were consistent with experimental observations
(Cito et al., 2013).
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3.3 Arterial and Venous Thrombi Formation
Blood flow in arteries and veins is a complex system that involves flow
loops with multiple branches where blood circulates (Ku, 1997). In arter-
ies, the type of flow observed is unsteady, with normal arterial flow being
laminar and secondary flows seen in curves and branches (Ku, 1997). One
of the challenges for modelers is that arteries and veins are living organs
that adapt and change to the various hemodynamic conditions to which
they are subjected. Sometimes the changes that arteries and veins make
can cause problems in clot formation. For instance, if velocity profiles
are skewed it can create areas in which wall shear stress oscillates (Ku,
1997; Lowe, 2003/2004). It is in these regions that atherosclerotic disease
is found. This disease causes the artery to become more narrow, creating
a stenosis, which can ultimately induce thrombosis and block blood flow
to the heart and brain (Ku, 1997). The reason this occurs is because the
stenosis causes turbulence and reduces flow through an artery, inducing
high shear stresses that can activate platelets and initiate clot formation
(Ku, 1997). In addition, these types of pathologies can also change the vis-
coelastic properties and viscosity of an individual’s blood (Fasano et al.,
2012). Thus, it is important to understand the consequences of different
types of flow in arteries and veins, and how different flow types can affect
physiological systems connected to the arteries and veins.
Some researchers have focused on the rheology of the vessels in the ar-
teries and veins. For example, Fasano et al. (2013) presents a model whose
aim is to capture the effect of blood slip at vessel walls. The authors claim
that the blood slip at vessel walls causes an increase in activated platelets
to the clotting site, which in some cases can even dominate the clotting
behavior of the system. Note that this model is based off of the cell-based
biological model of blood coagulation. Fasano et al. (2013) models the prop-
agation phase of the cell-based model of coagulation because this is when
the largest quantity of fibrin is produced, thus making it an easy species
to track. Because of the limited scope that was considered when modeling
the coagulation process, the results of this paper are themselves limited.
However, the authors recognize this and suggest that this model is a start
toward integrating blood slip phenomena into other coagulation models.
This model is significant because of its ability to predict blood slip conse-
quences, which are normally found around the bends and curves of the
venous and arterial systems (Fasano et al., 2013). These effects can be fur-
ther augmented depending on the blood vessel system: the arteries have
higher platelet counts than veins (Campbell et al., 2010; Fasano et al., 2013).
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Figure 3.4 Blood flow in selected systemic veins of the model. The compu-
tational results from the model are compared to the accepted literature results.
Image taken from Muller and Toro (2014)
On the other hand, other modelers have taken to directly modeling the
circulatory system. To demonstrate, Muller and Toro (2014) developed a
global multiscale mathematical model of the circulatory system, placing an
emphasis on the venous system. This work is novel because it includes a
majority of the circulatory system: arteries, veins, the heart, pulmonary cir-
culation, and microcirculation. The detailed venous system is what makes
Muller and Toro (2014) unique. In particular, the authors are interested in
understanding how neck and head venous hemodynamic conditions are
related to neurodegenerative diseases (Muller and Toro, 2014). In order to
develop a more accurate model, the authors use MRI data from individual
patients. Muller and Toro (2014) use a closed-loop, multiscale approach to
develop their model.
Figures 3.4 and 3.5 both show how well the experimental and accepted
literature values agree with the results of the model. To create these mod-
els, a 1D flow model was used in elastic vessels. Specifically, a first-order,
nonlinear hyperbolic system was used. Ultimately, these results provided
valuable insights and a holistic view of blood coagulation. However, one
34 Mathematical Models of Clot Formation Under Flow
Figure 3.5 This figure shows the blood flow in the head and neck veins of
an individual. The results from the model are directly compared to the results
collected from the MRI flow quantification images. Image taken from Muller and
Toro (2014)
of the disadvantages of such a model is that there is significantly more re-
search on arterial systems and not venous systems. Thus, more experimen-
tal research needs to be done to validate the results of the venous system.
3.4 Conclusions
To make models of blood coagulation more accurate, researchers have in-
corporated the blood flow dynamics observed in vivo. One of the difficul-
ties tog this type of modeling is that until the past decade, there were very
limited ways of quantifying and visualizing what physiological blood co-
agulation was like. As a result, there is more uncertainty in flow-based
models than in in vitro coagulation models.
Some of the fluid dynamics that have been successfully modeled in-
clude the rheology of blood, platelet deposition, flow-mediated transport,
and the overall growth and dissolution of clots. While these models make
several simplifications, they have helped move this field forward. How-
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ever, one of the challenges faced by modelers is in capturing the behavior
of whole blood as multiple types of fluids. Some of the earliest efforts in-
clude single continuum models. More recent work has used mixture theory
to model the different fluid types observed in the different components of
whole blood.
Future work may include more model validation. As limited exper-
imental data was available before the past few years, access to more data
will both help inspire different mathematical approaches and model valida-
tion techniques. It seems that it will become increasingly more important to
understand how venous and arterial systems differ from one another and
interact together in the coagulation system.

Chapter 4
Clinical and Pharmaceutical
Applications of Blood
Coagulation Models
Due to the critical role that blood coagulation plays in human physiology, it
is necessary to understand how we can diagnose and treat coagulation ab-
normalities. It is also important to understand how other diseases affect the
coagulation process. As a result, several mathematical models have been
used to directly study the pharmacology and diagnostics of coagulation
disorders and other diseases (Mann, 2012).
There are several challenges that researchers face in developing math-
ematical models of blood coagulation as they relate to pharmacology and
diagnostics. For instance, although the overall network of blood coagula-
tion is well-established, there is still not much understanding as to how it
works in vivo (Shibeko and Panteleev, 2015).
In this chapter, we will focus on the applications of mathematical mod-
eling directly to pharmacology and diagnostics. In particular, we will look
at models for pharmacokinetic-pharmacodynamic data, which seeks to un-
derstand drug-drug interactions and has seen an increasing use of systems
pharmacology models (e.g. Burghaus et al., 2011, 2014; Clegg and Gab-
hann, 2015; Cromme et al., 2010; de Pillis et al., 2015; Dydek and Chaikof,
2015; Gulati et al., 2014; Leipold et al., 1995; Luan et al., 2010; Lynd and
O’Brien, 2004; Mueck et al., 2011; Nagashima, 2002; Nayak et al., 2015;
Nielsen et al., 2009; Parunov et al., 2011, 2014; Vink et al., 2003; Wajima
et al., 2009). Pharmacology models are models that use ideas from systems
biology to simplify lumped parameter models (mostly multiscale models)
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to develop more mechanistic-based approaches (Gulati et al., 2014). Addi-
tionally, models that focus on providing individual profiles of disease risk
will be highlighted (e.g. Brummel-Ziedins, 2014; Brummel-Ziedins et al.,
2005; Lynd and O’Brien, 2004; Undas et al., 2010, 2011). Other models ad-
dress how preexisting conditions can affect coagulation (Clegg and Gab-
hann, 2015; Egger et al., 2013; Foley and Mackey, 2009; Lee et al., 2012; Lynd
and O’Brien, 2004; Singh et al., 2015; Undas et al., 2010, 2011) and other
possible areas of research such as using models to explore how biomedi-
cal devices and therapies, such as hemodialysis, affect coagulation (Barak
et al., 2008; Boccaccio and Medico, 2006; Cohen, 2012; Ghosh and Shetty,
2008; Moiseyev and Bar-Yoseph, 2013).
4.1 Modeling Pharmacokinetic-Pharmacodynamic Data
Understanding how therapeutic drugs affect the coagulation network is
important because it can help researchers quantify the effectiveness of each
drug. Mathematical models of coagulation can help researchers do this.
For example, a model of the biochemical network of coagulation can be
analyzed for points of fragility. These points could help indicate possi-
ble pathways or clotting factors that can be furthered explored for thera-
peutic intervention (Csajka and Verotta, 2006; Luan et al., 2010). Thus, the
uncertainties in mechanistic models can help focus the intervention of re-
searchers in clotting abnormalities.
4.1.1 Drug-Drug Interactions
Some of the questions that researchers are interested in exploring, among
many others, include:
1. How do different drug treatments affect the various coagulation path-
ways and thrombus formation?
2. How do different drugs interact with one another in the context of
coagulation?
3. How safe and effective are certain drugs when compared to others?
4. When do in vitro tests inaccurately portray in vivo conditions?
Similar types of questions have guided several of the models that have been
developed to date.
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An important note is that many of the models that specifically look at
the effectiveness of therapies use the international normalized ratio (INR)
measurements to quantify the effectiveness of anticoagulant treatments that
target vitamin-K antagonists (VKAs), such as warfarin (Christensen and
Larsen, 2012; Lazzaro and Zaidat, 2012). These values are based on PT and
aPTT tests (see Chapter 1). Note that higher INR values mean that it takes
longer for blood to clot. A safe target range for patients on anticoagulants
is an INR between 2.0 and 4.0 (Lazzaro and Zaidat, 2012). The INR of a
healthy individual is approximately 1.0 (Lazzaro and Zaidat, 2012).
Understanding Treatments of Clotting Abnormalities
Several models have been developed to understand clotting abnormalities
such as hemophilia or thrombosis. However, most of these models are not
developed with the purpose of modeling the disease itself. Instead, the
strategy employed is modeling healthy blood coagulation, modifying pa-
rameters associated with the clotting disorders, and ultimately modeling
how treatments of the clotting abnormalities affect the coagulation process.
In this section, we will focus on models that look at how drugs can help pa-
tients with hemophilia or thrombosis (Cromme et al., 2010; de Pillis et al.,
2015; Leipold et al., 1995; Nagashima, 2002; Nayak et al., 2015; Nielsen et al.,
2009; Parunov et al., 2011, 2014; Wajima et al., 2009). Some models focus on
thrombus formation and how it is affected by anticoagulants like warfarin
(Nielsen et al., 2009; Parunov et al., 2011), while other models incorporate
spatial and flow dynamics, along with drug interactions and their effect on
thrombus growth (de Pillis et al., 2015; Parunov et al., 2014).
One recent model that describes how the anticoagulant, warfarin, af-
fects thrombus growth was developed by de Pillis et al. (2015). In this
model, the authors extend past models of in vitro clot time tests and in vivo
thrombus formation that include warfarin treatments. de Pillis et al. (2015)
was particularly interested in describing possible conditions in which injury-
induced thrombi may form in vivo even when clot time tests (which are
used to diagnose and determine a patient’s ability to clot well) suggest that
warfarin treatments are performing at acceptable levels of anticoagulation.
In this study, the authors used a system of ODEs to model biochemical re-
actions and 1D laminar flow. Numerical simulations are used to compare
situations when warfarin dosages and flow conditions are varied under
normal physiological ranges. Ultimately, de Pillis et al. (2015) found that
one of the conventionally used clot time tests, INR measurements, do not
accurately describe in vivo clotting times. This model suggests that because
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the INR measurement does not account for the flow dynamics of blood, it
cannot describe in vivo clotting. Despite this meaningful claim, this model
makes several simplifications in its treatment of flow, warfarin interactions,
and coagulation biochemistry that limit the scope of its use. More details
and complexity can be added to this model to capture the effects of blood
flow, the pharmacokinetic-pharmacodynamic data, and even extend its use
to other treatments and applications (e.g., understanding biomedical im-
plants and their effects on coagulation and treatments).
Another comprehensive model that looks at in vitro tests, treatments,
and other applications is presented in Wajima et al. (2009). In this model,
the authors look at different in vitro tests and drug therapies using a simpli-
fied treatment of flow and the coagulation network. This model is extended
for applications to snake bites, hemophilia A and B, warfarin treatments,
and heparin treatments.
In Figure 4.1, the authors present the application of their model to aPTT
tests for hemophilia. Note that the x-axis shows % factor concentrations of
the normal plasma and the dotted lines show the 1%, 5%, and 25% of physi-
ological level for the respective factor concentrations. These concentrations
correspond to severe, moderate and mild disease, respectively. Ultimately,
Wajima et al. (2009) found that the standard aPTT results were consistent
with accepted literature values. The simulation showed that clotting time
ranges were 73-98 s and 79-123 s for patients with severe hemophilia A and
B, respectively (literature values are > 60 and > 80 s, respectively); 56-73
s and 59-79 s for patients with moderate hemophilia A and B, respectively
(literature values are 40-80s and 40-80 s, respectively); 43-56 s and 44-59 s
for patients with severe hemophilia A and B, respectively (literature values
are 40-60 s and 40-60 s for hemophilia A and B, respectively). Thus, the Wa-
jima et al. (2009) model accurately captures in vitro aPTT results for patients
with hemophilia A and B.
Similarly, in Figure 4.2 the authors show the results of simulations for
other clot time tests, namely the PT and aPTT results for literature data. In
general, the simulated tests agreed well with the measured values of the
tests, with the exception of the measurement of aPTT at 95 s. In this case,
the value was higher in the simulation than what was measured. Because
this model consistently reflects the measured values in its simulations, it
suggests the Wajima et al. (2009) model accurately captures the important
aspects of in vitro tests. While this model is able to successfully do this, it
simplifies the treatment of in vivo coagulation by using ODEs. However,
this model can be used in drug development and in predicting coagulation
kinetics.
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Rivaroxaban
Traditionally, warfarin and heparin are commonly used as anticoagulants
(Dahlback, 2000). However, a more recent oral anticoagulant known as
rivaroxaban has been receiving more attention because it is a direct fXa
inhibitor. Rivaroxaban is principally used to prevent venous thromboem-
bolism in adult patients.
When new drugs are developed, some of the many questions that arise
are: How safe and effective is the drug? How does the drug compare to
other therapies? What are the residual effects when a patient is switched
from one drug therapy to another? With regards to rivaroxaban, there are
two interesting models that have recently been developed (Burghaus et al.,
2011, 2014).
In Burghaus et al. (2011), the authors use a model to evaluate the effi-
cacy and safety of various rivaroxaban dosages. This model was based on
several published models (Bungay et al., 2003; Hockin et al., 2002; Kogan
et al., 2001; Kuharsky and Fogelson, 2001). The Burghaus et al. (2011) model
takes into account both the intrinsic and extrinsic pathways, blood flow dy-
namics and pharmacological mechanisms for certain drugs of interest. This
model was also applied to clinical studies.
Figure 4.3 shows the efficacy of rivaroxaban when compared with war-
farin. In the image, we note that at low TF concentrations, there is a large
overlap between warfarin and rivaroxaban. In contrast, at higher TF con-
centrations warfarin has a larger effect on clotting times. In particular,
this means that rivaroxaban has a higher dependency on TF concentra-
tions than warfarin when determining its anticoagulant effect. Thus, the
model suggests that at the particular dosage being looked at, rivaroxaban
has higher efficacy at low TF concentrations, where efficacy/potency are
defined as the ability to keep a patient’s clotting time at a safe level. At
higher concentrations, rivaroxaban is less effective than warfarin because
the higher TF concentrations induce stronger anticoagulant effects. This is
particularly important for patients with thrombosis since low potency at
high TF concentrations could lead to bleeding from the strong anticoagu-
lant effects of rivaroxaban. This is problematic because the drug therapies
should prevent over-clotting, but not at the risk of under-clotting.
Figure 4.4 shows the safety and efficacy of different doses of rivarox-
aban by comparing it with the following anticoagulants: ximelagatran,
enoxaparin, DX-9065a, and warfarin (Burghaus et al., 2011). Typical doses
for each of these drugs were compared with rivaroxaban doses ranging
from 5 mg to 40 mg. Based on the measure presented in Burghaus et al.
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(2011), all rivaroxaban doses were deemed safe up to 20 mg once daily
(OD) and doses were effective above 5 mg. It appears, from Figure 4.4, that
the optimal dose is at 20 mg OD. In this paper, a safe treatment was defined
as a treatment that had a safe INR level between 1.0 and 3.0. This is because
a safe INR for patients on anticoagulants is between 2.0 and 4.0 (Lazzaro
and Zaidat, 2012). Thus, this model captures the observed behavior of the
drugs and can be used to predict safe and effective rivaroxaban dosages for
treatment.
Later on Burghaus et al. (2014) used a similar model to investigate po-
tential dosing schedules for patients switching from warfarin to rivaroxa-
ban therapies. This is an important question because patients can have se-
vere drug reactions when they are switched to another anticoagulant ther-
apy, especially since residual effects of old treatments can remain present
for some time (Burghaus et al., 2014). This study used data from atrial
fibrillation patients in Caucasian and Japanese populations. Ultimately,
Burghaus et al. (2014) found that there was a synergetic reaction during the
first 2-3 days from warfarin discontinuation but the effect of warfarin was
additive after these first few days. Therefore, this model could be used to
determine dosage schedules for patients switching from one drug therapy
to another.
4.1.2 Systems Pharmacology Models
Many blood coagulation models are sophisticated multiscale models. How-
ever, the problem with using such models in clinical settings is that they
are so complex and detailed. One question of interest in modeling coagu-
lation is how might multiscale models be simplified so they can be used as
a mechanistic basis to estimate parameters that describe the relationship of
interest (Diamond, 2009). In Gulati et al. (2014), the authors present scale
reduction techniques to encourage the use of mechanistic models in clini-
cal pharmacology. Specifically, Gulati et al. (2014) uses a pharmacokinetic-
pharmacodynamic (PK-PD) model to describe the time course of recovery
after a brown snake bite. The authors use a lumping technique to simplify
a 62-state model to a 5-state model. The model describes the brown snake
venom-fibrinogen interaction and maintains an accurate mechanistic rela-
tionship of coagulation that agrees with experimental data.
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4.2 Developing Individual Profiles of Disease Risk
One of the goals of physicians is to be able to provide individualized care
for patients. Thus, it is of interest to understand an individual’s disease
risk. With regards to clotting disorders, one way that this may be done is by
using plasma-composition based models. These models are based on ear-
lier models of aPTT and PT diagnostics (Nayak et al., 2015). As more exper-
imental and clinical data is accessible for evaluation, new computational
and mathematical models are developed (Brummel-Ziedins, 2013, 2014).
One part of the coagulation network that is generally studied in indi-
vidual patients with possible prothrombotic phenotypes (or other types of
disease risk) is fXa generation (Brummel-Ziedins et al., 2012a, b, 2009). In
these types of models, factor levels of specific species were computed and
then used in the thrombin generation model to evaluate and determine pos-
sible causes of prothrombotic risk (Panteleev et al., 2014).
Thrombus formation in individuals can also be studied by looking at
platelet responses of patients. One such model is Flamm et al. (2012). Here,
a multiscale model of platelet deposition was used to compare simulated
thrombus formation with microfluidic experiments of thrombus growth
(Panteleev et al., 2014). This type of model can be used to assess throm-
botic phenotypes, diagnose new clotting abnormalities, and even evaluate
drug responses.
Other models look at individual thrombotic phenotypes based on pre-
existing health conditions associated with coagulation abnormalities. Among
the many health conditions explored are chronic obstructive pulmonary
disease (Undas et al., 2011), rheumatoid arthritis (Undas et al., 2010), can-
cer (Clegg and Gabhann, 2015; Lee et al., 2012), and deep vein thrombosis
(Brummel-Ziedins et al., 2005).
4.2.1 Areas of Further Research
Models of blood coagulation can provide great insight into various clin-
ical and pharmacological settings, as well as enhance the theoretical un-
derstanding of the coagulation phenomenon. Some possible extensions of
such models include further investigations of other diseases and disorders
linked with coagulation abnormalities, such as atrial fibrillation, malaria,
or cancer Boccaccio and Medico (2006); Clegg and Gabhann (2015); Foley
and Mackey (2009); Ghosh and Shetty (2008); Kulo et al. (2011); Vogler and
Siedlecki (2009).
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Other applications may include analysis of blood coagulation of pa-
tients undergoing surgery or the consequences of long-term use of biomed-
ical implants or therapies (Barak et al., 2008; Cohen, 2012; Diamond, 1999;
Dudek et al., 2011b, a; Moiseyev and Bar-Yoseph, 2013; Spahn and Casutt,
2000; van de Vosse, 2003). For instance, patients with end-stage renal fail-
ure that are under hemodialysis (HD) can take in microbubbles created in
the HD machine (Barak et al., 2008). This is problematic because microbub-
bles can obstruct blood flow, initiate coagulation, and even cause platelets
to adhere to the bubble itself, further triggering coagulation (Barak et al.,
2008). Thus, coagulation models can serve to develop engineering systems
that are less harmful for patients. In fact, some of these same principles can
be extended to develop models for bone regeneration and tissue engineer-
ing (Geris et al., 2010).
4.3 Conclusions
The clinical and pharmaceutical applications of blood coagulation mod-
els are numerous. They can be used to understand the drug pathways in-
volved in treatments and the effect of those pathways on the overall coag-
ulation network. Additionally, models can be used to determine the safety
and efficacy of drug therapies and diagnostic tests. Recently, more work
has been done in understanding how the plasma composition of an indi-
vidual can be used to determine the individual’s risk of disease. These
types of models take into account thrombus formation under flow, possible
treatments the individual may be taking, and even preexisting health con-
ditions that have been linked with coagulation abnormalities. Ultimately,
these types of models are useful in quantifying the effectiveness of certain
drug developments and the health risks of an individual.
Despite the wealth of insight these models can provide, they are not yet
commonly used in developing drugs (Shibeko and Panteleev, 2015). These
models continue to be used as theoretical models for understanding coag-
ulation biochemical mechanisms. Some of the disadvantage of using these
models is that many of them continue to rely on the coagulation cascade
biological model. The problem with basing work off of these biological co-
agulation models is that the general consensus is that a cell-based model
is more accurate (Bodnár et al., 2014; Fasano et al., 2013). It is not yet clear
how using the cell-based model of blood coagulation would alter some of
these findings, particularly since it seems that these coagulation cascade-
based models reflect the observed results of clinical and PK-PD data.
Conclusions 45
Figure 4.1 This figure shows simulation results of the influence of (a) defi-
ciency of fVIII (for hemophilia A) and (b) deficiency of fIX (for hemophilia B), as
seen in aPTT tests. The x-axis is shows % factor concentrations of the nor-
mal plasma and the dotted lines show the 1%, 5%, and 25% of physiological
level for the respective factor concentrations. The aPTT simulations had initial
concentrations of 14.8% of fXI and fXIa. Image taken from Wajima et al. (2009)
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Figure 4.2 The simulated PT and aPTT compared withe measured literature
values. (a) PT on a normal scale graph, (b) PT on a log-log scale, (c) aPTT on
a normal scale graph, and (d) aPTT on a log-log scale graph. The aPTT and PT
were simulated using factor concentrations from literature. The PT simulations
assumed an initial TF concentration of 300 nmol/l, meaning there was an excess
of fVII concentration. The aPTT simulations assumed and initial concentration of
14.8% and 33.9% for fXI and fXIa in plasma samples, respectively. Image taken
from Wajima et al. (2009)
Conclusions 47
Figure 4.3 Efficacy of warfarin and rivaroxaban treatments are compared. A
dose of 20 mg once daily (OD) of rivaroxaban was compared to warfarin with
1.5 < INR < 3. The clotting times are measured as functions of TF concen-
trations. The dark region represents the overlap of rivaroxaban and warfarin.
Image taken from Burghaus et al. (2011)
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Figure 4.4 Safety and effectiveness of different anticoagulant treatments at
varying dosages. The error bars show the spread of clotting times. (A) The red
shaded area illustrates safe clotting times above the effect of warfarin titrated to
an INR of 3. All therapies below the red area are considered safe. Here the
trigger for coagulation is TF 10−11 mol/l. (B) The trigger is fXIIa 10−11 mol/l.
(C) The trigger is TF 10−14 mol/l. (D) The trigger is TF 10−11 mol/l. The green
area represents the effect of warfarin to an INR of 1.5. All values above the
green shaded region are considered effective. Image taken from Burghaus et al.
(2011)
Chapter 5
Conclusions
Blood coagulation is a complex physiological process that is critical to an
individual’s health. It involves a balance of various factors including bio-
chemical reactions, clotting factors, platelets, binding sites, geometrical and
spatial constraints from the blood vessels, and flow dynamics. When an im-
balance exists, an individuals life can be at risk. Some of the dangers of ab-
normally clotting are significant blood loss, pulmonary embolism, throm-
bosis, stroke, cardiac arrest, or even death (Tanaka et al., 2009). As a result,
blood coagulation research is an important topic in medical research. How-
ever, there are many disagreements as to the validity of the models because
of the uncertainty in parameters and the disagreement between experimen-
tal and simulated data (Hemker and Ataullakhanov, 2005; Hemker et al.,
2012). This is, in part, due to the lack of understanding of the physical
effects of physiological coagulation (Hemker et al., 2012; Leiderman and
Fogelson, 2014).
Given the complexity of coagulation, mathematicians can use mathe-
matical models to quantify the coagulation process. Mathematical models
allow researchers to gain insight into the nuances of clotting, as well as pro-
vide an avenue for testing potential treatments and drug therapies when a
physical experiment may be too dangerous (Mann, 2012). In this review,
we have grouped mathematical models based on what they attempt to de-
scribe: in vitro coagulation, in vivo coagulation, and clinical applications.
5.1 In Vitro Coagulation
In vitro models focus on understanding the basic biochemistry of coagu-
lation. These models assume that there is no flow in the coagulation pro-
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cess, making them ideal for predicting coagulation behavior in experimen-
tal and non-vascular environments. As a result, these models form the ba-
sis of mathematical models of diagnostic tests, such as the activated partial
thromboplastin time test or prothrombin time test.
Mathematicians have primarily used ODE-based models to simulate
clotting, honing in on specific biochemical mechanisms of the coagulation
process. Given the deterministic nature of the models, the uncertainty in
parameters plays a great role in the results of the models. There have, how-
ever, been several efforts to perform a sensitivity analysis of the in vitro
models developed to date. Additionally, to account for the uncertainty in
parameters and in the stochastic behavior observed, mathematicians have
also used Monte Carlo simulations and Petri net models.
While these types of models have provided a greater understanding of
the biochemical processes involved in coagulation, they do not accurately
characterize physiological coagulation. There are several sources of uncer-
tainty in coagulation models, including rate constant measurement, indi-
vidual plasma-content variation, or clotting factor variations, that have yet
to be thoroughly explored.
5.2 In Vivo Coagulation
Other models have incorporated the blood flow dynamics of in vivo coag-
ulation. However, because of the greater uncertainty in how the physical
parameters of coagulation affect clot formation, these models are difficult
to construct. Despite the uncertainty, some of the aspects of coagulation
that have been successfully modeled include the rheology of blood, platelet
deposition, flow-mediated transport, and the dissolution of clots.
Most of these models use a PDE-based multiscale modeling approach.
This work has even allowed for the modeling of different types of blood
vessels (i.e., arteries and veins). With more experimental data becoming
available, in vivo coagulation models promise to become more important in
clinical research and drug development.
5.3 Clinical Applications
With more reliable models of in vitro and in vivo coagulation, clinical re-
searchers and scientists are using mathematical models more and more in
their work. Some of the topics that mathematical models have allowed re-
searchers to explore include drug-drug interactions, the safety and efficacy
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of drug therapies, dosing schedules, individual disease risk, and the design
of biomedical technologies.
Models used in clinical and pharmaceutical applications are based on
the simple mathematical models of in vitro coagulation. In spite of the in-
accuracy of in vitro mathematical models, the use of these models has sug-
gested the inadequacy of current diagnostic tests used by physicians. As
such, more recent work has begun to include flow dynamics.
5.4 The Future of Mathematical Modeling of Coagu-
lation
Over the past few years, there has been a growing interest in modeling
clotting abnormalities and pharmacokinetic-pharmacodynamic data. In
particular, emphasis has been placed in modeling the effects of different
drug therapies on the coagulation system. This type of work has resulted
in more sophisticated, computationally intensive multiscale models (Pan-
teleev et al., 2007). Many of these models rely heavily on mathematical
models of in vitro coagulation. However, doing so means that critical phys-
iological factors (e.g., blood flow dynamics) are ignored, resulting in less ac-
curate results. More recent models are starting to incorporate flow, spatial-
temporal constraints, and even the individual plasma composition of pa-
tients.
Mathematical modeling of blood coagulation will continue to be rele-
vant in years to come. As more accurate models continue to be developed,
new uses for these models will emerge. Currently, these models are used
to quantify in vitro diagnostics and understand the biochemical underpin-
nings of normal coagulation. They have also shown great potential in help-
ing to develop drugs, understand how preexisting conditions in a patient
affect drug therapies and coagulation, and design biomedical engineering
systems that are beneficial for patients. However, until the mathematical
models used in clinical settings better capture physiological coagulation
behavior, clinicians will continue to use the less than perfect in vitro mod-
els. This could be improved by the development of a new diagnostic assay
that better describes the current hemostatic state of a patient (Foley et al.,
2013; Gulati et al., 2012; Shibeko and Panteleev, 2015), or by incorporating
the physical constraints of coagulation in models. Ultimately, further in-
vestigations of the blood coagulation system and its physical parameters
are needed to improve mathematical models.
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Glossary
A
activated partial thromboplastin time test
A diagnostic test done to evaluate your blood’s ability to clot. It mea-
sures the time needed for a plasma sample to clot. This test uses less
TF to initiate clotting than the PT test, but still only evaluates the ex-
trinsic pathway. 12, 49
B
binding sites
Regions on a surface (in this case, platelets), where specific proteins
and clotting factors can bind to and form a chemical bond. Binding
sites play a key role in coagulation because many of the reactions can
only take place if the clotting factors and proteins are bound to an
activated platelet. 8, 16, 20, 49
blood
Transports nutrients and oxygen throughout the body, and eliminates
wastes via blood vessels. It contains plasma, red blood cells, white
blood cells, platelets, and other proteins. 2
blood coagulation
A series of biochemical reactions that take place in order for a blood
clot to form. This is the last step in hemostasis and is what stabilizes
initial clots formed in hemostasis. 2
C
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cell-centric model of hemostasis
A biological model of how blood coagulation works. This model is
characterized by its treatment of the intrinsic and extrinsic pathway.
It states that they work in parallel during coagulation but on different
surfaces: the intrinsic pathway works on platelets and the extrinsic
pathway works on TF-bearing cells. 4, 6
clotting factor
A protein in the blood that helps control blood coagulation and bleed-
ing. 2, 4, 11, 49
coagulation cascade
A biological model of how blood coagulation works. The distin-
guishing feature of this model is that the intrinsic and extrinsic path-
way work separately to address different steps in blood coagulation.
Eventually, the two pathways meet up in a common pathway and
form a stabilized clot. 4, 5, 12, 29
complex
A substance formed when one or more clotting factors or proteins are
chemically bounded. 5
E
extrinsic pathway
An important pathway that forms part of blood coagulation. This
pathway is faster than the intrinsic pathway and is initiated by tissue
factor (TF). The extrinsic pathway generates small amounts of throm-
bin (fIIa) via interactions of fVII. 4, 12, 16, 29
F
fibrin
A fibrous mesh of polymer protein strands that form during coagula-
tion. Fibrin and platelets stick and interlace to form a stabilized clot,
which is the ultimate end goal of coagulation. 2, 5
H
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hemophilia
A hereditary bleeding disorder that is characterized by under-clotting.
There are two types of hemophilia: hemophilia A (corresponding to
fVIII deficiency) and hemophilia B (corresponding to fIX deficiency).
Hemophilia varies in the severity of its symptoms between individ-
uals, but can be dangerous because of the potential for significant
blood loss. 11, 12, 39, 40
hemostasis
A subsystem of the cardiovascular system whose purpose is to pre-
vent blood loss while maintaining blood in a fluid state within the
vascular system. In this process, clots are formed when blood ves-
sels are damaged and anticoagulants, along with other processes, are
used to regulate clot formation. 1, 2
I
international normalized ratio
A measurement of an individual’s ability to clot. It is based on the PT
and aPTT tests. When looking at international normalized ratio (INR)
values, higher INR values mean it takes longer for blood clot to form.
This suggests a risk of bleeding. Lower INR values indicate faster clot
times, suggesting a risk of thrombosis. Note that a healthy individual
with no coagulation abnormalities has an INR of approximately 1.0.
INR values are usually used to measure the effectiveness of anticoag-
ulant treatments that target vitamin-K antagonists (VKAs). 38
intrinsic pathway
An important pathway that forms part of blood coagulation. This
pathway is slower than the extrinsic pathway and is initiated by in-
ternal trauma to the blood vessels. The intrinsic pathway is respon-
sible for sustaining coagulation, produce a boost in thrombin con-
centration, and stabilize the soft plug formed in the early stages of
hemostasis. 4, 16, 29
M
multiscale model
A sophisticated type of mathematical model that incorporates vari-
ous submodels of different parts of a much larger system. By com-
partmentalizing different facets of a process, these models are able to
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include more detail about the phenomena they seek to describe. 29,
37, 42, 43
P
plasma
The fluid part of blood. It contains all of the proteins, enzymes and
clotting factors needed to form a blood clot. Note that plasma inside
the body must be flowing and contain anticoagulants for it to remain
a fluid. For experiments where plasma is left standing, a large con-
centration of anticoagulants are added to keep it from clotting com-
pletely. 2
platelet
Cell fragments that are found in blood. Platelets come in two states:
activated and inactivated. When a platelet is activated, clotting fac-
tors can bind to corresponding binding sites on platelet surfaces to
allow the necessary biochemical reactions to take place and form a
clot. Platelets also adhere to the site of injury to form a plug. 2, 4, 8,
11, 16, 20, 49
prothrombin time test
A screening laboratory test, or diagnostic test, done to determine how
long it takes for your blood to clot. It works by adding significant
amounts of TF to a blood plasma sample. This particular test is only
able to evaluate the extrinsic pathway, ignoring other major parts of
the coagulation system. 12, 49
S
stenosis
The abnormal narrowing of a blood vessel. Note that this is different
from vascoconstriction because vascoconstriction is part of hemosta-
sis, whereas stenosis is a result of other health complications. 31
T
thrombin
Also known as factor IIa (fIIa). This is an enzyme that converts fib-
rinogen to fibrin. Its generation is the penultimate step before a clot
can be stabilized. 6, 16
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thrombosis
A bleeding disorder characterized by over-clotting. The symptoms
and severity of thrombosis can vary greatly between individuals. Throm-
bosis poses a large risk because it can lead to strokes, cardiac arrest,
damage to vital organs, or even death. 19, 31, 39
tissue factor
A protein that acts as the key initiator to blood coagulation. It is also
known as thromboplastin, or factor II (fII). 4
V
vascoconstriction
The narrowing of blood vessels from the contraction of blood vessel
tissues. This is the first, immediate step in hemostasis. It helps reduce
blood loss when there is damage to the blood vessel. 2
